China listed stock

• KE Holdings Inc. rose 4% before trading, after falling nearly 20% in the previous three days.

After three consecutive days of weakening and falling nearly 20 per cent, KE Holdings Inc. rebounded before trading, rising 3.96 per cent to $61.70.

Yesterday, KE Holdings Inc. announced that it would publicly price its additional 35.4 million shares of ADS (American depositary shares) at $58 per ADS, each representing three Class A common shares. The offering is expected to be completed on November 23, 2020.

The company plans to use the proceeds from the sale to expand its range of services, expand to new regions and invest in its infrastructure, identify potential strategic opportunities, as well as for working capital and general corporate purposes.

• Bilibili Inc. rose 2% before trading and has risen more than 200% so far this year.

Bilibili Inc. rose 2% before trading, and its share price broke through the $60 mark before trading, and has risen more than 200% so far this year.

Bilibili Inc. 's third-quarter results greatly exceeded expectations, the company's revenue hit another record high in the third quarter, paying users nearly doubled compared with the same period last year, and the number of monthly active users exceeded 200m. Bilibili Inc. directly led to a 22% rise yesterday to an all-time high, with a market capitalization exceeding 20 billion US dollars.

• "domestic first share" Yatsen soared more than 75% on the first day of listing, and rose more than 14% before trading.

Yatsen, the parent company of the well-known domestic beauty make-up brand perfect Diary, was officially listed on the New York Stock Exchange yesterday. The stock rose as much as 98 per cent to $20.80 a day, nearly doubling the IPO offering price and closing up more than 75 per cent.

It rose more than 14% to $21.02 before trading today.

Active US stocks before the day

• BioNTech SE rose more than 5% before the market, and the European Union agreed to purchase 300 million doses of its vaccine from drug companies such as BioNTech.

According to reports, the head of the European Commission said that the EU may have the conditions to approve the sale of health incident vaccines of Pfizer Inc, BioNTech and Moderna Inc in late December.

Affected by the news, BNTX rose by more than 5% before trading, and Pfizer Inc rose by more than 3% and 1% respectively. Other concepts of anti-epidemic have risen one after another.

The EU agreed to buy its 300m doses of vaccine from Pfizer Inc and BioNTech at a price lower than that paid by the US, according to people familiar with the matter. In addition, the EU will also buy vaccines from Germany's CureVac, which means the EU may spend more than $10 billion on vaccine purchases.

• Gilead fell more than 1% before trading, World Health Organization (WHO) does not recommend using Reed Sivir to treat COVID-19

Gilead was down 1.86% in premarket trading. World Health Organization (WHO) 's international panel of experts said in a statement that it is not recommended to use Gilead Dexivir to treat COVID-19 patients, because there is still no evidence to prove that it has a significant effect on patient mortality and other aspects.

The proposal is part of a dynamic guide developed with the support of the MAGIC Evidence Ecosystem Foundation methodology of the World Health Organization's international guidelines, which aims to provide reliable guidance to the management of COVID-19 and to help doctors make better decisions for patients.